Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment

Weintraub, W. S., Bhatt, D. L., Zhang, Z., Dolman, S., Boden, W. E., Bress, A. P., King, J. B., Bellows, B. K., Tajeu, G. S., Derington, C. G., Johnson, J., Andrade, K., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J.-C., Ballantyne, C. M., & Kolm, P. (2022). Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Network Open, 5(2), e2148172. https://doi.org/10.1001/jamanetworkopen.2021.48172
Authors:
William S Weintraub
Deepak L Bhatt
Zugui Zhang
Sarahfaye Dolman
William E Boden
Adam P Bress
Jordan B King
Brandon K Bellows
Gabriel S Tajeu
Catherine G Derington
Jonathan Johnson
Katherine Andrade
P Gabriel Steg
Michael Miller
Eliot A Brinton
Terry A Jacobson
Jean-Claude Tardif
Christie M Ballantyne
Paul Kolm
Affiliated Authors:
Brandon K Bellows
Publication Type:
Article
Unique ID:
10.1001/jamanetworkopen.2021.48172
PMID:
Publication Date:
Data Source:
PubMed

Record Created: